Welcome to our dedicated page for Sagimet Biosciences SEC filings (Ticker: SGMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sagimet Biosciences Inc. (NASDAQ: SGMT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sagimet is a clinical-stage biopharmaceutical company developing oral fatty acid synthase (FASN) inhibitors for metabolic and fibrotic diseases, and its filings offer detailed insight into this development strategy, capital structure, and risk profile.
Through Forms 8-K, Sagimet reports material events such as clinical trial updates, license agreements, accounting firm changes, at-the-market equity sales arrangements, and quarterly financial results. For example, recent 8-K filings describe positive Phase 1 pharmacokinetic data for a denifanstat and resmetirom combination, a global license agreement with TAPI for innovative forms of resmetirom active pharmaceutical ingredient to support a fixed-dose combination program, and financial results for recent quarters. Other 8-Ks outline changes in the company’s independent registered public accounting firm and the establishment of an at-the-market offering program for its Series A common stock.
Investors and analysts can use this page to locate Sagimet’s periodic and current reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q when available, which typically contain information on clinical development progress for denifanstat and TVB-3567, funding arrangements, and risk factors related to MASH and acne programs. Forms 4 and other ownership-related filings, when present, can be used to monitor insider transactions in SGMT shares.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents, helping readers quickly understand the significance of new 10-Ks, 10-Qs, and 8-Ks. Real-time updates from EDGAR ensure that new Sagimet filings appear promptly, while AI-generated highlights can clarify complex topics such as licensing terms, at-the-market sales agreements, and clinical trial disclosures. This makes the SGMT filings page a practical starting point for reviewing Sagimet’s regulatory history and ongoing obligations.
Sagimet Biosciences reported 2025 results and outlined progress across its MASH, acne and oncology programs. For 2025, total operating expenses were $56.9 million and net loss was $51.0 million, compared with a $45.6 million net loss in 2024. Fourth-quarter 2025 net loss was $9.6 million versus $16.2 million a year earlier. Cash, cash equivalents and marketable securities were $113.1 million as of December 31, 2025, which the company expects will fund operations through the third quarter of 2027.
Clinically, denifanstat continued to show strong Phase 2b data in MASH, including statistically significant improvements in steatohepatitis and fibrosis, and positive safety. A Phase 1 pharmacokinetic trial of a denifanstat/resmetirom combination was completed, with a Phase 2 trial in MASH cirrhosis (F4) planned for the second half of 2026. In acne, partner Ascletis’ Phase 3 trial of denifanstat met all primary and secondary endpoints, and China’s regulator accepted an NDA for moderate to severe acne in 2025.
Sagimet also highlighted its follow‑on FASN inhibitor TVB‑3567, now in a first‑in‑human Phase 1 trial for acne, and exploratory oncology work targeting FASN‑dependent tumors, supporting a multi‑indication pipeline built around FASN inhibition.
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on fatty acid synthase (FASN) inhibitors for liver disease, acne and cancer. Its lead oral FASN inhibitor, denifanstat, achieved statistically significant Phase 2b results in MASH, improving liver fat, inflammation and fibrosis biomarkers and was generally well tolerated.
Denifanstat received FDA Breakthrough Therapy designation in October 2024 for non-cirrhotic MASH with F2–F3 fibrosis, and Sagimet has completed end-of-Phase 2 FDA interactions. A Phase 1 pharmacokinetic trial combining denifanstat with THR-β agonist resmetirom showed no safety signals, supporting a planned Phase 2 proof-of-concept trial in F4 MASH in the second half of 2026, subject to regulatory consultation.
In acne, China partner Ascletis reported that denifanstat met all primary and secondary endpoints in a 480-patient Phase 3 trial in moderate to severe acne and that the China NMPA accepted its NDA in December 2025. An open-label Phase 3 extension showed generally well-tolerated long-term use. Sagimet is also developing oral FASN inhibitor TVB-3567, now in a first-in-human Phase 1 acne study with a Phase 2 start anticipated in 2026, and is exploring oncology applications where tumors depend on FASN-driven lipid metabolism.
Rozek Elizabeth reported acquisition or exercise transactions in this Form 4 filing.
Sagimet Biosciences Inc. reported that Chief Legal & Administrative Officer Elizabeth Rozek received new equity awards. She was granted an option to buy 88,000 shares of Series A Common Stock, vesting in 48 equal monthly installments starting February 19, 2026. She was also awarded 44,000 restricted stock units, each representing one share of Series A Common Stock, vesting in four equal annual installments from the same date, contingent on continued service.
Sagimet Biosciences Chief Medical Officer Eduardo Bruno Martins reported equity awards that increase his direct holdings. He received a stock option covering 88,000 shares of Series A Common Stock at an exercise price of $0.00 per share, and a separate grant of 44,000 shares of Series A Common Stock in the form of restricted stock units (RSUs).
The RSUs will vest in four equal annual installments after February 19, 2026, contingent on continued service. The stock option will vest in forty-eight equal monthly installments after the same date, also subject to continued service. Following these transactions, his reported direct ownership of Series A Common Stock is 147,296 shares, and he holds options for 88,000 shares.
Sagimet Biosciences President & CEO and director David Happel reported awards of equity-based compensation. He was granted 256,000 stock options with an exercise right to buy Series A Common Stock at $0.00 per share, and 128,000 restricted stock units (RSUs) for Series A Common Stock.
The RSUs vest in four equal annual installments following February 19, 2026, conditioned on his continued service. The options vest in forty-eight equal monthly installments after the same date, also tied to continued service. Following the RSU grant, his reported Series A Common Stock holdings total 805,621 shares.
Sagimet Biosciences Inc. reported that its Chief Financial Officer, Thierry Chauche, received new equity awards. He was granted a stock option for 88,000 shares at an exercise price of $0.0000 per share, which will vest in forty-eight equal monthly installments following February 19, 2026, subject to continued service.
Chauche also acquired 44,000 shares of Series A Common Stock in the form of restricted stock units. Each RSU represents one share and will vest in four equal annual installments following February 19, 2026, contingent on his continued service on each vesting date. After this award, his directly held Series A Common Stock totaled 59,688 shares.
Sagimet Biosciences Inc. President & CEO and director David Happel reported an automatic sale of Series A Common Stock. On 02/10/2026, 12,101 shares were sold at $5.3603 per share to cover tax withholding obligations related to vesting restricted stock units. After this transaction, he beneficially owned 677,621 shares directly. The filing notes these tax-related sales were automatic and not at his discretion.
Sagimet Biosciences Chief Financial Officer Thierry Chauche reported an automatic sale of Series A Common Stock largely tied to tax obligations. On February 10, 2026, he sold 1,312 shares at $5.3603 per share in an open-market transaction.
According to the disclosure, the shares were required to be sold to cover tax withholding arising from the vesting of restricted stock units, and the sales were automatic rather than discretionary. After this transaction, Chauche directly beneficially owned 15,688 shares of Sagimet Biosciences common stock.
Sagimet Biosciences’ Chief Medical Officer reports automatic share sale to cover taxes. Martins Eduardo Bruno sold 3,640 shares of Series A Common Stock on February 10, 2026 at an average price of $5.3602 per share in an open-market transaction.
According to the footnote, the sale was required to cover tax withholding obligations tied to vesting restricted stock units and was executed automatically, not at his discretion. After this transaction, he directly beneficially owned 103,296 shares of Sagimet Biosciences Inc.
Sagimet Biosciences Inc. Chief Legal & Admin. Officer Elizabeth Rozek reported an automatic sale of 2,622 shares of Series A Common Stock on February 10, 2026 at an average price of $5.3602 per share. After this tax-related sale, she beneficially owns 190,959 shares directly.
The shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units, and the filing states that these sales were automatic and not made at her discretion.